With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
(Web Desk) - The harmful effects of air pollution on health, including an increased risk of cancer, have been well-documented ...
TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
“Head and neck squamous cell carcinoma remains a deadly disease with limited treatment options,” added Dr. Le Tourneau. “With its strong clinical outcomes across a large dataset of patients, ...
Application error: a client-side exception has occurred (see the browser console for more information).
Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today ...
Bicara Therapeutics Inc. (BCAX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.Don't Miss our Black Friday ...
BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung ...